

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 8247)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of Directors (the “**Director(s)**”) of Biosino Bio-Technology and Science Incorporation (the “**Company**”) announces that Prof. Shen Jiangan (沈劍剛教授) (“**Prof. Shen**”) has been appointed as an independent non-executive Director with effect from 23 February 2023.

The biographical details of Prof. Shen are as follows:

Prof. Shen Jiangan (沈劍剛教授)

Prof. Shen Jiangan, aged 59, has been appointed as an independent non-executive Director with effect from 23 February 2023. Prof. Shen acted as a professor and chairman of the Departmental Research Postgraduate Committee at School of Chinese Medicine of The University of Hong Kong since February 2022. From July 2014 to February 2020, Prof. Shen acted as a professor and associate director (research) of School of Chinese Medicine at The University of Hong Kong. From January 2013 to July 2014, Prof. Shen acted as a professor and assistant director (research) of School of Chinese Medicine at The University of Hong Kong. From November 2005 to January 2007, Prof. Shen acted as an assistant professor at School of Chinese Medicine of The Chinese University of Hong Kong. From August 2004 to December 2005, Prof. Shen served as an assistant professor (research) at College of Pharmacy, Health Science Center, University of New Mexico in the United States of America (the “**United States**”). From September 2001 to September 2004, Prof. Shen served as a research assistant professor at the Department of Medicine of The University of Hong Kong. From August 1999 to September 2001, Prof. Shen was employed as a research scientist at National EPR Center, Department of Radiology at Dartmouth Medical School in the United States. From July 1995 to July 1998, Prof. Shen acted as an associate professor and associate director at Institute of Chinese Medicine, Nan-Fang Hospital, First Military Medical University (currently known as Southern Medical University) in China. From July 1990 to July 1995, Prof. Shen was a lecturer at Institute of Chinese Medicine, Nan-Fang Hospital, First Military Medical University in China.

In addition, Prof. Shen held numerous other management positions. Prof. Shen has served as a member of the Common Core Curriculum Committee and the Medical Education and Health Sciences Institute Professional Development Committee of Li Ka Shing Faculty of Medicine of The University of Hong Kong since 2014 and 2013, respectively. Prof. Shen has also served as a member of the Chinese Medicine Research and Development Committee at the Hospital Authority of Hong Kong since 2008 and served as a member of the Chinese Medicine division at the Chinese Medicine Council of Hong Kong from 2014 to 2020. Prof. Shen has also been a member of the Chinese Medicine Industry Division of the Hong Kong Chinese Medicine Council of the Health and Welfare Bureau of Hong Kong from 2021 and 2020, respectively; and a member of the Chinese Medicine Research and Development Committee of the Hong Kong Innovation and Technology Commission since 2020.

Prof. Shen obtained his doctorate degree at the Institute of Biophysics Chinese Academy of Science in July 1998, his master's degree in Medical Science in Integrated Medicine at Sun Yat-sen University of Medical Science (中山醫科大學) in August 1998 and his bachelor's degree of Medicine at the Hunan Chinese Medical University (湖南中醫學院) in July 1984. Prof. Shen was also a postdoctoral research fellow at Anesthesia Research Laboratories, Brigham and Women's Hospital and Harvard Medical School, Boston, the United States from September 1998 to August 1999.

Prof. Shen entered into a service agreement with the Company and his term of service with the Company will end at the expiry of the term of the current session of the Board. His remuneration will be determined by the Board and the remuneration committee of the Company with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

As at the date of this announcement, Prof. Shen does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company, its subsidiaries or any of its associated corporations which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement, Prof. Shen does not (i) have any relationship with any other Directors, senior management, or substantial or controlling shareholders (each as defined in the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the “**GEM Listing Rules**”)) of the Company; (ii) hold any other position with the Company or any of its subsidiaries; and (iii) hold any other directorships in public companies whose securities are listed on any securities market in Hong Kong or overseas in the preceding three years.

To the best knowledge, information and belief of the Directors and having made all reasonable enquiries, save as disclosed above, there is no information relating to Prof. Shen that is required to be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules, and there are no other matters in relation to the appointment of Prof. Shen that is required to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board would like to express its warmest welcome to Prof. Shen in joining the Board.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

Prof. Shen was appointed as a member of each of the audit committee of the Company (the “**Audit Committee**”), the nomination committee of the Company (the “**Nomination Committee**”) and the remuneration committee of the Company (the “**Remuneration Committee**”) with effect from 23 February 2023. The composition of the Audit Committee, the Nomination Committee and the Remuneration Committee were changed as follows:

Audit Committee Dr. Zheng Yongtang (*Chairman*)
Mr. Lu Qi
Prof. Shen Jiangang

Nomination Committee Mr. Lu Qi (*Chairman*)
Dr. Zheng Yongtang
Mr. Wu Lebin
Prof. Shen Jiangang

Remuneration Committee Dr. Zheng Yongtang (*Chairman*)
Mr. Lu Qi
Prof. Shen Jiangang

COMPLIANCE WITH THE GEM LISTING RULES

Following Prof. Shen's appointment, the Board comprises seven members, including two executive Directors, two non-executive Directors and three independent non-executive Directors. The current number of independent non-executive Directors complies with Rule 5.05(1) of the GEM Listing Rules. In addition, the Company fulfils the requirements of having a minimum of three members on the Audit Committee under Rule 5.28 of the GEM Listing Rules and having a majority of independent non-executive Directors on the Remuneration Committee under Rule 5.34 of the GEM Listing Rules.

By Order of the Board
Biosino Bio-Technology and Science Incorporation
Tung Woon Cheung, Eric
Company Secretary

Beijing, the People's Republic of China, 24 February 2023

As at the date of this announcement, the Board comprises:

Chairman and executive Director

Mr. Wu Lebin (吳樂斌先生)

Vice chairman and non-executive Director

Dr. Sun Zhe (孫哲博士)

Vice chairman and executive Director

Mr. Lin Yanglin (林楊林先生)

Non-executive Director

Ms. Cheng Yali (程亞利女士)

Independent non-executive Directors

Dr. Zheng Yongtang (鄭永唐博士), Prof. Shen Jiangang (沈劍剛教授) and Mr. Lu Qi (陸琪先生)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at <http://www.hkexnews.hk> for a minimum of seven days from the date of its publication and on the website of the Company at www.zhongsheng.com.cn.